پذیرفته شده و در حال انتشار                   برگشت به فهرست مقالات | برگشت به فهرست نسخه ها

Ethics code: IR.TUMS.SPH.REC.1400.011

XML English Abstract Print


چکیده:   (158 مشاهده)

Background and Objectives: Breast cancer is the second leading cause of cancer-related mortality in women and is influenced by genetic, environmental, and lifestyle factors. This study aimed to evaluate the prevalence of risk factors in breast cancer patients and their association with disease progression and survival.
Materials and Methods: A retrospective analysis was conducted on 400 breast cancer patients treated between 2011 and 2021 at Sina and Farmaniyeh hospitals in Tehran. The study evaluated clinical factors like hypertension, diabetes, and hyperlipidemia, alongside reproductive histories and lifestyle factors such as smoking and oral contraceptive use. Tumor characteristics and 5-year survival outcomes were analyzed using logistic regression and Kaplan-Meier methods.
Results: Hypertension was correlated with advanced tumor stages (P = 0.048) and higher grades (P = 0.025). Early menarche is associated with lymphovascular involvement (P = 0.005) and an increased risk of metastasis (P = 0.049). Additionally, smoking significantly raised the risk of lymphovascular invasion (P < 0.001). Survival analysis revealed a non-significant trend toward reduced 5-year survival in hypertensive patients (log-rank P = 0.288), with cumulative hazard curves indicating higher mortality rates. No significant associations were found for diabetes, family history, or contraceptive use.
Conclusion: The results indicate that hypertension is linked to aggressive tumor characteristics, potentially affecting disease progression. Although the connection to survival was not statistically significant, the increased risk in hypertensive patients calls for further research. Additionally, early menarche and smoking correlate with negative tumor features, emphasizing the need to monitor hypertension and address lifestyle factors in breast cancer management.

     
نوع مطالعه: مقاله پژوهشی | موضوع مقاله: Clinical Medicine
دریافت: 1404/3/7 | پذیرش: 1404/5/1 | انتشار: 1404/5/17

فهرست منابع
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. [DOI:10.3322/caac.21660] [PMID]
2. Wang X, Wang N, Zhong L, Wang S, Zheng Y, Yang B, et al. Prognostic value of depression and anxiety on breast cancer recurrence and mortality: a systematic review and meta-analysis of 282,203 patients. Mol Psychiatry. 2020;25(12):3186-97. [DOI:10.1038/s41380-020-00865-6] [PMID] [PMCID]
3. Kabel AM. Tumor markers of breast cancer: New prospectives. J Oncol Sci. 2017;3(1):5-11. [DOI:10.1016/j.jons.2017.01.001]
4. Obeagu EI, Obeagu GU. Breast cancer: A review of risk factors and diagnosis. Medicine. 2024;103(3):e36905. [DOI:10.1097/MD.0000000000036905] [PMID] [PMCID]
5. Moseson M, Koenig KL, Shore RE, Pasternack BS. The Influence of Medical Conditions Associated with Hormones on the Risk of Breast Cancer. Int J Epidemiol. 1993;22(6):1000-9. [DOI:10.1093/ije/22.6.1000] [PMID]
6. Chowdhury FA, Islam MF, Prova MT, Khatun M, Sharmin I, Islam KM, et al. Association of hyperlipidemia with breast cancer in Bangladeshi women. Lipids Health Dis. 2021;20(1):52. [DOI:10.1186/s12944-021-01480-2] [PMID] [PMCID]
7. Han H, Guo W, Shi W, Yu Y, Zhang Y, Ye X, et al. Hypertension and breast cancer risk: a systematic review and meta-analysis. Sci Rep. 2017;7(1):44877. [DOI:10.1038/srep44877] [PMID] [PMCID]
8. Boyle P, Boniol M, Koechlin A, Robertson C, Valentini F, Coppens K, et al. Diabetes and breast cancer risk: a meta-analysis. Br J Cancer. 2012;107(9):1608-17. [DOI:10.1038/bjc.2012.414] [PMID] [PMCID]
9. Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cífková R, Dominiczak AF, et al. Hypertension. Nat Rev Dis Primers. 2018;4:18014. [DOI:10.1038/nrdp.2018.14] [PMID] [PMCID]
10. Farhadi F, Aliyari R, Ebrahimi H, Hashemi H, Emamian MH, Fotouhi A. Prevalence of uncontrolled hypertension and its associated factors in 50-74 years old Iranian adults: a population-based study. BMC Cardiovasc Disord. 2023;23(1):318. [DOI:10.1186/s12872-023-03357-x] [PMID] [PMCID]
11. Kim KI. Hypertension in Older Women: The Biggest Challenge for Cardiovascular Health in an Aged Society. Korean Circ J. 2022;52(5):393-4. [DOI:10.4070/kcj.2022.0036] [PMID] [PMCID]
12. Yankaskas BC. Epidemiology of breast cancer in young women. Breast Dis. 2005;23:3-8. [DOI:10.3233/BD-2006-23102] [PMID]
13. Williams MS, Beech BM, Griffith DM Jr, Thorpe RJ. The Association between Hypertension and Race/Ethnicity among Breast Cancer Survivors. J Racial Ethn Health Disparities. 2020;7(6):1172-7. [DOI:10.1007/s40615-020-00741-7] [PMID] [PMCID]
14. Goldberg M, Díaz-Santana MV, O'Brien KM, Zhao S, Weinberg CR, Sandler DP. Gestational Hypertensive Disorders and Maternal Breast Cancer Risk in a Nationwide Cohort of 40,720 Parous Women. Epidemiology. 2022;33(6):868-79. [DOI:10.1097/EDE.0000000000001511] [PMID] [PMCID]
15. Yue W, Tran HT, Wang JP, Schiermeyer K, Gildea JJ, Xu P, et al. The Hypertension Related Gene G-Protein Coupled Receptor Kinase 4 Contributes to Breast Cancer Proliferation. Breast Cancer (Auckl). 2021;15:11782234211015753. [DOI:10.1177/11782234211015753] [PMID] [PMCID]
16. Wang W, He Q, Zhang H, Zhuang C, Wang Q, Li C, et al. A narrative review on the interaction between genes and the treatment of hypertension and breast cancer. Ann Transl Med. 2021;9(10):894. [DOI:10.21037/atm-21-2133] [PMID] [PMCID]
17. Fan Y, Khan NH, Farhan Ali Khan M, Ahammad MDF, Zulfiqar T, Virk R, et al. Association of Hypertension and Breast Cancer: Antihypertensive Drugs as an Effective Adjunctive in Breast Cancer Therapy. Cancer Manag Res. 2022;14:1323-9. [DOI:10.2147/CMAR.S350854] [PMID] [PMCID]
18. Mazzuferi G, Bacchetti T, Islam MO, Ferretti G. High density lipoproteins and oxidative stress in breast cancer. Lipids Health Dis. 2021;20(1):143. [DOI:10.1186/s12944-021-01562-1] [PMID] [PMCID]
19. Ferroni P, Riondino S, Buonomo O, Palmirotta R, Guadagni F, Roselli M. Type 2 Diabetes and Breast Cancer: The Interplay between Impaired Glucose Metabolism and Oxidant Stress. Oxid Med Cell Longev. 2015;2015:183928. [DOI:10.1155/2015/183928] [PMID] [PMCID]
20. Zhu H, Doğan BE. American Joint Committee on Cancer's Staging System for Breast Cancer, Eighth Edition: Summary for Clinicians. Eur J Breast Health. 2021;17(3):234-8. [DOI:10.4274/ejbh.galenos.2021.2021-4-3] [PMID] [PMCID]
21. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334-57. [DOI:10.1161/HYPERTENSIONAHA.120.15026] [PMID]
22. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care. 2023;47(Supplement_1):S20-S42. [DOI:10.2337/dc24-S002] [PMID] [PMCID]
23. Rezaianzadeh A, Namayandeh SM, Sadr SM. National Cholesterol Education Program Adult Treatment Panel III Versus International Diabetic Federation Definition of Metabolic Syndrome, Which One is Associated with Diabetes Mellitus and Coronary Artery Disease?. Int J Prev Med. 2012;3(8):552-8.
24. Weismiller DG. Menopause. Prim Care - Clin Off Pract. 2009;36(1):199-226. [DOI:10.1016/j.pop.2008.10.007] [PMID]
25. Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press). 2019;11(null):151-64. [DOI:10.2147/BCTT.S176070] [PMID] [PMCID]
26. Kozłowska K, Kozłowski L, Małyszko J. Hypertension prevalence in early breast cancer patients undergoing primary surgery. Adv Med Sci. 2019;64(1):32-6. [DOI:10.1016/j.advms.2018.10.003] [PMID]
27. Ma J, Li Y, Yang X, Liu K, Zhang X, Zuo X, et al. Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8(1):168. [DOI:10.1038/s41392-023-01430-7] [PMID] [PMCID]
28. Powe DG, Voss MJ, Zänker KS, Habashy HO, Green AR, Ellis IO, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget. 2010;1(7):628-38. [DOI:10.18632/oncotarget.197] [PMID] [PMCID]
29. Wong GW, Boyda HN, Wright JM. Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension. Cochrane Database Syst Rev. 2016;3(3):Cd007451. [DOI:10.1002/14651858.CD007451.pub2]
30. Madel MB, Elefteriou F. Mechanisms Supporting the Use of Beta-Blockers for the Management of Breast Cancer Bone Metastasis. Cancers (Basel). 2021;13(12):2887. [DOI:10.3390/cancers13122887] [PMID] [PMCID]
31. Jung SY, Rosenzweig M, Sereika SM, Linkov F, Brufsky A, Weissfeld JL. Factors associated with mortality after breast cancer metastasis. Cancer Causes Control. 2012;23(1):103-12. [DOI:10.1007/s10552-011-9859-8] [PMID]
32. Ritte R, Lukanova A, Tjønneland A, Olsen A, Overvad K, Mesrine S, et al. Height, age at menarche and risk of hormone receptor-positive and -negative breast cancer: A cohort study. Int J Cancer. 2013;132(11):2619-29. [DOI:10.1002/ijc.27913] [PMID]
33. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13(11):1141-51. [DOI:10.1016/S1470-2045(12)70425-4] [PMID]
34. Yang P-J, Hou M-F, Ou-Yang F, Tsai E-M, Wang T-N. Association of early-onset breast cancer with body mass index, menarche, and menopause in Taiwan. BMC Cancer. 2022;22(1):259. [DOI:10.1186/s12885-022-09361-2] [PMID] [PMCID]
35. Fuhrman BJ, Moore SC, Byrne C, Makhoul I, Kitahara CM, Berrington de González A, et al. Association of the Age at Menarche with Site-Specific Cancer Risks in Pooled Data from Nine Cohorts. Cancer Res. 2021;81(8):2246-55. [DOI:10.1158/0008-5472.CAN-19-3093] [PMID] [PMCID]
36. Orgéas CC, Hall P, Rosenberg LU, Czene K. The influence of menstrual risk factors on tumor characteristics and survival in postmenopausal breast cancer. Breast Cancer Res. 2008;10(6):R107. [DOI:10.1186/bcr2212] [PMID] [PMCID]
37. Subramaniam S, Kong YC, Zaharah H, Uiterwaal C, Richard A, Taib NA, et al. Baseline cardiovascular comorbidities, and the influence on cancer treatment decision-making in women with breast cancer. Ecancermedicalscience. 2021;15:1293. [DOI:10.3332/ecancer.2021.1293] [PMID] [PMCID]
38. Henry Mariana L, Niu J, Zhang N, Giordano Sharon H, Chavez-MacGregor M. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients. JACC Cardiovasc Imaging. 2018;11(8):1084-93. [DOI:10.1016/j.jcmg.2018.06.005] [PMID] [PMCID]
39. Clift AK, Dodwell D, Lord S, Petrou S, Brady SM, Collins GS, et al. The current status of risk-stratified breast screening. Br J Cancer. 2022;126(4):533-50. [DOI:10.1038/s41416-021-01550-3] [PMID] [PMCID]
40. Patnaik JL, Byers T, DiGuiseppi C, Denberg TD, Dabelea D. The Influence of Comorbidities on Overall Survival Among Older Women Diagnosed With Breast Cancer. J Natl Cancer Inst. 2011;103(14):1101-11. [DOI:10.1093/jnci/djr188] [PMID] [PMCID]

بازنشر اطلاعات
Creative Commons License این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است.

کلیه حقوق این وب سایت متعلق به Journal of Advances in Medical and Biomedical Research می باشد.

طراحی و برنامه نویسی : یکتاوب افزار شرق

© 2025 CC BY-NC 4.0 | Journal of Advances in Medical and Biomedical Research

Designed & Developed by : Yektaweb